Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Immunologic and placental responses to the VSV-EBOV vaccine in a pregnant mouse model
Aaron P. Lewkowicz, Yiru Wang, Mirian I. Mendoza, Kaliroi Engel, Logan Kelley-Baker, Iara Rattner, Amber Lopez, Ian L. McWilliams, Derek D.C. Ireland, Mohanraj Manangeeswaran, Ha-Na Lee, Daniela Verthelyi, Sandra M. Blois
Aaron P. Lewkowicz, Yiru Wang, Mirian I. Mendoza, Kaliroi Engel, Logan Kelley-Baker, Iara Rattner, Amber Lopez, Ian L. McWilliams, Derek D.C. Ireland, Mohanraj Manangeeswaran, Ha-Na Lee, Daniela Verthelyi, Sandra M. Blois
View: Text | PDF
Research Article Infectious disease Reproductive biology

Immunologic and placental responses to the VSV-EBOV vaccine in a pregnant mouse model

  • Text
  • PDF
Abstract

Ebola virus disease is a severe viral hemorrhagic illness with high maternal and perinatal mortality. Although the replication-competent vesicular stomatitis virus–based Ebola vaccine (VSV-EBOV) has been deployed successfully in outbreak settings, pregnant women were excluded from clinical trials, leaving critical safety gaps. To address this, we developed a murine model to assess pregnancy outcomes following VSV-EBOV exposure at different gestational stages. Pregnant C57BL/6 mice vaccinated at embryonic day 7 (E7), E10, or E15 mounted robust anti–Ebola virus (anti-EBOV) antibody responses comparable to those of non-pregnant controls and efficiently cleared the vaccine virus without evidence of vertical transmission. However, peri-implantation vaccination modestly increased fetal resorption and early postnatal mortality, accompanied by placental pathology characterized by vascular remodeling defects and inflammation. Later gestational vaccination had minimal impact on survival or offspring development. Mechanistic studies revealed that these adverse effects were mediated by type I interferon signaling rather than direct viral infection, as IFN-β–deficient mice exhibited normal pregnancy outcomes and blocking interferon receptor activity ameliorated placental pathology despite higher viral loads. To our knowledge, these findings represent the first comprehensive preclinical safety evaluation of VSV-EBOV vaccination during pregnancy and identify a critical window of vulnerability early in gestation. More broadly, this work underscores the central role of interferons in shaping placental immune responses and provides an experimental framework to guide evaluation of live-virus vaccines in pregnancy.

Authors

Aaron P. Lewkowicz, Yiru Wang, Mirian I. Mendoza, Kaliroi Engel, Logan Kelley-Baker, Iara Rattner, Amber Lopez, Ian L. McWilliams, Derek D.C. Ireland, Mohanraj Manangeeswaran, Ha-Na Lee, Daniela Verthelyi, Sandra M. Blois

×

Figure 5

Blockade of type I IFN signaling in vaccinated pregnant dams increases viral load and fetal resorption while attenuating vaccine-induced placental alterations.

Options: View larger image (or click on image) Download as PowerPoint
Blockade of type I IFN signaling in vaccinated pregnant dams increases v...
(A) Schematic of the experimental design. Pregnant C57BL/6 mice received anti-IFNAR antibodies (aIFNAR; 0.6 mg, i.p.) at E6 and were challenged with 105 TCID50 VSV-EBOV at E7, followed by sacrifice at E12. Uninfected control pregnant C57BL/6 mice (No Vac) were sacrificed at E12. (B) Maternal body weight (BW) was monitored at E6 (baseline), 3 dpc, and 5 dpc. Weight changes are shown relative to E6. Data are presented as mean ± SD (n = 3–9 mice per group). (C) Viral loads in dams and embryos were quantified by TCID50 assay. Dashed lines indicate the limit of detection (LoD = 316 TCID50). (D–F) Fetal outcomes at E12, including the rate of resorbed fetuses (D), fetal body weight (E), and developmental stage assessed by Theiler staging (TS) (F) in the indicated groups. Data are shown as mean ± SD. Number of fetuses per group is indicated within the pie charts. (G) Glycogen-rich cells were assessed by PAS staining. The graph shows the proportion of PAS+ cells within the junctional zone (JZ). GCs, glycogen cells. (H) SpA remodeling was evaluated by Masson-Goldner trichrome staining. (I and J) DBA/PAS staining of E12 placental sections showing accumulation of mature uNK cells. Double-positive (DBA+PAS+) tissue-associated uNK (I) and vascular-associated uNK (J) cells. In G–J, data from control (No Vac) and vaccinated (E7 Vac) groups are shown again for reference alongside the anti-IFNAR–treated vaccinated (aIFNAR + E7 Vac) group. Data are presented as mean ± SD (n = 6–9 per group). *P < 0.05, **P < 0.01, as determined by 1-way ANOVA followed by Holm-Šidák multiple-comparison test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts